Sin inhibitors represent a class of chemical compounds designed to target and modulate the activity of Sirtuin (SIR) proteins, a family of NAD+-dependent deacetylases involved in various cellular processes. Sirtuins play a critical role in gene expression, metabolism, and the regulation of cellular stress responses. Sin inhibitors function by interfering with the catalytic activity of these enzymes, typically through direct binding to the active site or through allosteric modulation. By altering the activity of Sirtuins, these inhibitors can affect various post-translational modifications, such as the deacetylation of histones and non-histone proteins, ultimately influencing chromatin structure, transcriptional regulation, and metabolic pathways.
At a molecular level, Sin inhibitors are structurally diverse and can be designed to target specific Sirtuin isoforms, as Sirtuin family members (SIRT1–SIRT7) have distinct cellular functions and tissue distributions. The inhibition mechanism often involves the disruption of the enzyme's interaction with NAD+, a cofactor essential for Sirtuin function, thereby impeding its deacetylase activity. The selective inhibition of different Sirtuin isoforms allows for fine-tuning of their respective roles in cellular homeostasis, such as mitochondrial biogenesis, cell cycle regulation, and apoptosis. These inhibitors are frequently studied in the context of their ability to modulate various cellular signaling pathways and metabolic processes, especially those related to energy expenditure, oxidative stress, and DNA repair mechanisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a potent, selective, and ATP-competitive inhibitor of Src family kinases, including Fyn. It blocks the phosphorylation and activation of these kinases, indirectly affecting eFAS/Sin signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, known for its action against BCR-ABL and Src family kinases. By inhibiting Src kinases, it can indirectly modulate eFAS/Sin activities. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib is a selective inhibitor of Src family kinases. It binds to the ATP binding site, reducing kinase activity and thereby influencing eFAS/Sin-related signaling pathways. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 (Ponatinib) is a multi-target kinase inhibitor, effective against BCR-ABL and Src family kinases. It can indirectly impact eFAS/Sin signaling through Src inhibition. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 is a selective Src family kinase inhibitor. By targeting these kinases, it indirectly modulates the pathways involving eFAS/Sin. | ||||||
PD 173955 | 260415-63-2 | sc-507378 | 10 mg | $320.00 | ||
PD173955 is a potent inhibitor of Src and Bcr-Abl kinases. Its inhibition of Src kinases may indirectly influence eFAS/Sin signaling pathways. | ||||||
WH-4-023 | 837422-57-8 | sc-507457 | 10 mg | $172.00 | ||
WH-4-023 is a selective inhibitor of Lck and Src family kinases, which could modulate eFAS/Sin activity by inhibiting these related kinases. | ||||||
KX2-391 | 897016-82-9 | sc-364520 sc-364520A | 5 mg 50 mg | $180.00 $1140.00 | ||
KX2-391 is a non-ATP competitive inhibitor of Src kinases, potentially influencing eFAS/Sin signaling through this pathway inhibition. | ||||||